000			01625 a2200433 4500
005			20250515170827.0
264		0	_c20090803
008			200908s 0 0 eng d
022			_a2694-233X
024	7		_a10.1377/hlthaff.28.3.783 _2doi
040			_aNLM _beng _cNLM
100	1		_aWang, Philip S
245	0	0	_aImproving mental health treatments through comparative effectiveness research. _h[electronic resource]
260			_bHealth affairs (Project Hope) _c
300			_a783-91 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article
650	0	4	_aAlzheimer Disease _xdrug therapy
650	0	4	_aAntidepressive Agents _xadverse effects
650	0	4	_aAntipsychotic Agents _xadverse effects
650	0	4	_aCost-Benefit Analysis
650	0	4	_aDepressive Disorder, Major _xdrug therapy
650	0	4	_aDrug Costs _xstatistics & numerical data
650	0	4	_aEvidence-Based Medicine _xeconomics
650	0	4	_aHealth Policy _xeconomics
650	0	4	_aHumans
650	0	4	_aInsurance Coverage
650	0	4	_aInsurance, Pharmaceutical Services
650	0	4	_aMental Disorders _xdrug therapy
650	0	4	_aPsychotic Disorders _xdrug therapy
650	0	4	_aPsychotropic Drugs _xeconomics
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aSchizophrenia _xdrug therapy
650	0	4	_aTreatment Outcome
650	0	4	_aUnited States
700	1		_aUlbricht, Christine M
700	1		_aSchoenbaum, Michael
773	0		_tHealth affairs (Project Hope) _gvol. 28 _gno. 3 _gp. 783-91
856	4	0	_uhttps://doi.org/10.1377/hlthaff.28.3.783 _zAvailable from publisher's website
999			_c18843838 _d18843838